김승용 정연복 표희수 권오승 2024-01-20T23:01:08Z 2024-01-20T23:01:08Z 2021-09-06 2008-08 2093-5552 https://pubs.kist.re.kr/handle/201004/133266 A sensitive and simple method of determining the plasma levofloxacin (LFX, CAS 100986-85-4) concentrations in human volunteers by liquid-liquid extraction were developed and validated by using a high-performance liquid chromatography/diode array detector. The method was also applied to armacokinetic study of LFX. LFX was orally administered to 8 healthy male Korean volunteers at single lowest dose of 200 mg, compared to the published reports in which more than 500 mg of LFX was orally administered. LFX in human plasma was determined. The detection limit of LFX was 0.05 μg/mL. Cmax value was 2.48 ± 0.67 μg/mL. AUC0→24 hr and AUC0→∞ were 14.52 ± 3.35 μg/mL and 16.00 ± 3.66 μg · hr/mL, respectively. The terminal half-life was 6.87±0.46 hr. Our pharmacokinetic parameters were very consistent with that previously reported, showing good correlation between LFX doses and AUC (r2=0.995). This method can be useful for the pharmacokinetics and bioequivalence study with relatively low dose for reducing the main side effects of LFX. English 한국약제학회 Pharmacokinetic Analysis of Levofloxacin in Healthy Korean Volunteers Article 2 Journal of Pharmaceutical Investigation, v.38, no.4, pp.235 - 240 Journal of Pharmaceutical Investigation 38 4 235 240 N kci ART001270102 Levofloxacin Antibiotics Pharmacokinetics Human volunteers High-performance liquid chromatography